Media coverage
3
Media coverage
Title United States : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Tendernews.com Country/Territory India Date 9/11/22 URL ct.moreover.com/?a=49207814661&p=1gw&v=1&x=kO4gewrpEgxBsRIr6RcGVA Persons Ajai Chari Title United States : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet TendersInfo – News Country/Territory India Date 8/11/22 URL ct.moreover.com/?a=49208003646&p=1gw&v=1&x=PfcSNSZb6eXGiWvaT4Pt4w Persons Ajai Chari Title United States : U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Media name/outlet Mena Report Country/Territory United Kingdom Date 8/11/22 URL ct.moreover.com/?a=49206820639&p=1gw&v=1&x=m6SjiQCUQWxAlmy9Dj3HpA Persons Ajai Chari